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doi:10.1016/j.jmii.2011.12.014Background/Purpose: Prosthetic joint infection (PJI) has become an important issue in the
management of patients who receive prostheses. We compared the clinical outcomes of PJIs
caused by Gram-negative bacteria (GN PJIs) and Gram-positive bacteria (GP PJIs).
Methods: Patients with culture-proven PJIs admitted to China Medical University Hospital
between March 2001 and March 2009 were included in this retrospective study.
Results: Fifty-nine patients were diagnosed with PJI during the study period. Nineteen
patients had GN PJIs (mean age: 68 years) and 40 had GP PJIs (mean age: 61 years). The most
common comorbid condition was diabetes mellitus (23.7%) and the most common presentation
was joint pain (79.7%). Staphylococcus aureus was the most common pathogen, whereas
Klebsiella pneumoniae was the most common Gram-negative pathogen. The GN PJI group
included more cases of hematogenous infection (36.8% vs. 20%; p < 0.001), showed a shorter
interval between onset of infection symptoms and surgical intervention (median: 8 days vs. 21
days; p Z 0.04), and required longer medical treatment (median: 259 days vs. 161 days;
p Z 0.04). In comparison with patients whose prostheses were eventually removed, patients
whose prostheses were not removed had a shorter interval between onset of infection symp-
toms and surgical intervention (median: 6 days vs. 90 days; p Z 0.004 and median: 6 days vs.
44 days; p Z 0.04) in the GP PJI and GN PJI groups, respectively.fectious Diseases, Department of Internal Medicine, China Medical University Hospital, No. 2 Yuh-Der
447, Taiwan.
me.com.tw (M.-W. Ho).
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364 S.-W. Tseng et al.Conclusion: GN PJI was less common than GP PJI, but GN PJI was more complicated and
required longer treatment. Prospective randomized clinical studies are needed to investigate
whether prosthesis implantation should be reserved if the patient undergoes early surgical
intervention for PJI.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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With the improvements in medical and surgical therapy,
joint replacements are now being widely performed.1,2 In
Taiwan, an increasing number of patients are undergoing
joint-replacement procedures for the lower extremities.3e5
Patients who undergo joint replacement show improvement
in the quality of life and wellbeing. However, they may
also experience several complications, such as infection,
aseptic loosening, periprosthetic fractures, all of which can
lead to prosthesis dysfunction.2,6 Infection, which occurs in
0.39e3% of cases,7e10 is the most important and serious
complication,7,11 and increases the medical costs associ-
ated with joint replacement.12
Current strategies to manage prosthetic joint infection
(PJI) include prosthesis removal with or without two-stage
reimplantation, and prosthesis retention with adequate
debridement and long-term antibiotic therapy.13,14
Although it has been reported to be a mainstay of treat-
ment,15 prosthesis removal with or without two-stage
reimplantation may cause immobilization and prolonged
rehabilitation, and has a high surgical risk. Debridement
with retention of the prosthesis, which has been suggested
in selected cases,16 may require prolonged antibiotic
treatment and is associated with high rates of treatment
failure. These two treatment strategies may be indicated in
different clinical entities, such as PJIs caused by Gram-
positive or Gram-negative bacteria. However, only a few
studies have discussed the difference in treatment and
clinical outcome between PJIs caused by Gram-positive
bacteria (GP PJI) and those caused by Gram-negative
bacteria (GN PJI). Therefore, with the aim of reporting
our clinical experience of managing PJIs, with particular
emphasis on the outcomes of different strategies for
treating GP PJI and GN PJI, we initiated this retrospective
study in a teaching hospital in Taiwan.
Materials and methods
Patient selection
Patients who were diagnosed with their first episode of
monomicrobial PJI and were treated at China Medical
University Hospital (a 2000-bed tertiary teaching hospital
in Central Taiwan) between March 2001 and March 2009
were included in our study. Using the electronic system of
medical records and charts, we included the information of
all patients who, according to the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification,
matched the criteria for PJI (code 996.66). We excluded
cases with incomplete charts, no postoperative follow-updata, or poor drug compliance. We recorded demographic
data for each patient, including information about comor-
bidity, disease presentations, laboratory findings, and clin-
ical management. Cases of GP PJI and GN PJI were
compared for risk of treatment failure and clinical outcome.
All patients were followed up from the diagnosis of PJI until
the last outpatient visit or admission to our hospital.
Definition
Diagnosis of PJI was based on: (1) isolation of the same
microorganism from two or more joint aspirates; (2)
detection of inflammation in histopathological examina-
tions and the presence of at least one positive culture in
the intraoperative specimens; or (3) infectious symptoms
such as a discharging sinus tract communicating with the
prosthesis, or a purulent joint space observed during
surgery.14,17e20
Relapse of infection was defined as PJI caused by the
same microorganism that was isolated previously. Reinfec-
tion was defined as PJI caused by a microorganism different
from that isolated from the previous PJI. Treatment failure
was considered to be unsuccessful under the following
conditions: (1) relapse of infection; (2) reinfection; (3)
histopathological evidence of periprosthetic tissue inflam-
mation; (4) purulent joint or occurrence of a sinus tract;
and (5) death due to prosthesis-related infection.14,17e20
Hematogenous route of infection was considered if the
patient had no history of direct bacterial invasion (invasive
procedure or penetrating trauma) or local spread (osteo-
myelitis, cellulitis, and abscess) in the prior 3 months.21,22
Statistical analysis
We used SPSS for Windows version 12.0 (SPSS, Chicago, IL,
USA) for analyzing the clinical comparisons. The c2 or
Fisher’s exact test was used to analyze categorical data,
and Student’s t test was used to analyze continuous vari-
ables. A two-tailed p value <0.05 was considered statisti-
cally significant.
Results
We followed all patients in our study group for at least 24
months (range: 25e96 months). Fifty-nine patients with
PJI, including 19 (32.2%) with GN PJI and 40 (67.8%) with GP
PJI, were included in our study. The demographic charac-
teristics of the patients are listed in Table 1. The median
ages of the GN PJI and GP PJI patients were 68 years and 61
years, respectively. Twenty-six patients (44%) had under-
lying diseases: diabetes mellitus was the most common
Table 1 Demographic characteristics of patients with GN PJI and GP PJI
Characteristics GN PJI (n Z 19) GP PJI (n Z 40) p value
Age (yr), median age (range) 68 (27e84) 61 (34e85) 0.92
Male sex 14 (73.6) 21 (52.5) 0.34
Hematogenous route 7 (36.8) 8 (20) <0.001
Prosthesis age, median days (range)
Symptom durationa 91 (7e2880) 100 (7e2160) 0.04
median days (range) 8 (2e155) 21 (1e120) 0.04
Clinical symptoms
pain 14 (73.6) 33 (82.5) 0.12
swelling 12 (63.1) 29 (72.5) 0.82
limited range of motion 3 (15.7) 19 (47.5) 0.59
local heat 3 (15.7) 15 (37.5) 0.59
fever (38.3C) 1 (5.2) 7 (17.5) 0.80
discharge sinus 7 (36.8) 17(42.5) 0.51
Comorbidity
DM 3 (15.7) 11 (27.5) 0.42
ESRD 1 (5.2) 3 (7.5) NA
gouty arthritis 1 (5.2) 4 (10) NA
liver cirrhosis 0 (0) 3 (7.5) NA
Laboratory finding, median (range)
ESR (mm/hr) 67.1 (7e140) 71.4 (16e140) 0.72
WBC (103 cells/mL) 8.1 (3.90e19.10) 9.1 (4.23e38.67) 0.24
hsCRP (mg/dL) 5.8 (0.07e29.55) 8.8 (1.50e43.58) 0.18
Treatment
hospital stay, median days (range) 31 (15e107) 22 (14e80) 0.07
total treatment days,b median days (range) 259 (109e1979) 161 (60e877) 0.04
debridement, median times (range) 1 (0e4) 2 (0e5) 0.81
Number (%) of patients, unless indicated. Data with p < 0.05 were considered to be statistically significant.
DM Z diabetes mellitus; ESR Z erythrocyte sedimentation rate; ESRD Z end-stage renal disease; GN PJI Z Gram-negative prosthetic
joint infection; GP PJI Z Gram-positive prosthetic joint infection; hsCRP Z high sensitivity C-reactive protein; NA Z not applicable;
WBC Z white blood cells.
a Duration of infectious symptoms prior to surgical intervention.
b Duration included medical and surgical treatment.
Prosthetic joint infection 365comorbid condition and was reported in 14 cases (23.7%).
The most common symptoms of PJI were pain (47 cases,
79.6%) and swelling (41 cases, 69.5%), while fever was
present in eight (13.6%).
The interval between onset of infection symptoms and
surgical intervention was shorter in the GN PJI group than in
the GP PJI group (median: 8 days vs. 21 days; p Z 0.04).
Moreover, the duration of hospital stay tended to be
longer in GN PJI patients than in GP PJI patients (median:
31 days vs. 22 days; p Z 0.07). The total treatment dura-
tion, including the time required for surgical and antibiotic
treatment, was also longer in GN PJI patients (median: 259
days vs. 161 days; p Z 0.04).
Table 2 lists the microorganisms that caused PJI in our
study. Staphylococcus aureus was the most common caus-
ative pathogen. Furthermore, most of the GN PJIs were
caused by Klebsiella pneumoniae (4 cases, 21.1%), followed
by Pseudomonas aeruginosa (3 cases, 15.8%) and Escher-
ichia coli (3 cases, 15.8%). When the cases of PJI were
divided into three time-based groups: after implantation
to early infection (<3 months); delayed infection (3e24
months); and late infection (>24 months), GP PJIs
accounted for 17 (42.5%), 17 (42.5%), and six (15%) cases,and GN PJI accounted for nine (47.4%), three (15.8%), and
seven (36.8%) cases, respectively. Virulent Gram-positive
bacteria such as S. aureus (28 cases in total) tended to
occur in early (16 cases, 57.1%) and late (5 cases, 17.9%)
infection, whereas Gram-negative bacterial infections were
also relatively common in these two stages. Compared to
GP PJIs, GN PJIs showed a higher degree of correlation
with a hematogenous route of infection (36.8% vs. 20%;
p < 0.001).
Patients with GP PJIs received intravenous antibiotic
treatment for at least 3e4 weeks; 29 patients (72.5%)
received antibiotic monotherapy, and 11 patients (27.5%)
received combined antibiotic therapy. One patient who
was treated with intravenous antibiotics for 2 weeks died
from PJI during the follow-up period. The antibiotic mon-
otherapy regimen included treatment with vancomycin or
teicoplanin in nine cases (22.5%), oxacillin in 17 cases
(42.5%), (3) cefazolin in two cases (5%), and moxifloxacin in
one case (2.5%). The combined antibiotic therapy regimen
included treatment with vancomycin or teicoplanin
combined with rifampicin in 11 cases (27.5%). Fusidic acid
and rifampicin were used to treat methicillin-resistant
S. aureus, and cloxacillin or fusidic acid was used to treat
Table 2 Microbiological findings in cases of GN PJI and GP
PJI
Microorganism Case number (%)
Gram-positive bacteria 40 (100%)
Staphylococcus aureus
methicillin-sensitive S. aureus 15 (37.5%)
methicillin-resistant S. aureus 13 (32.5%)
Coagulase-negative staphylococci 5 (12.5%)
Streptococcus spp. 5 (12.5%)
Enterococcus faecalis 1 (2.5%)
Peptostreptococcus prevotii 1 (2.5%)
Gram-negative bacteria 19 (100%)
Enteral bacteria
Klebsiella pneumoniae 4 (21.1%)
Escherichia coli 3 (15.8%)
other speciesa 5 (26.2%)
Nonenteral bacteria
Pseudomonas aeruginosa 3 (15.8%)
other speciesb 4 (21.1%)
GN PJI Z Gram-negative prosthetic joint infection; GP PJI Z
Gram-positive prosthetic joint infection.
a included Enterobacter cloacae (2 cases), Salmonella chol-
eraesuis (2 cases), and Proteus mirabilis (1 case).
b included Stenotrophomonas maltophilia (1 case), Acineto-
bacter baumannii (2 cases), and Acinetobacter lwoffii (1 case).
366 S.-W. Tseng et al.other microorganisms; these antibiotics were selected for
oral antibiotic switch in cases of GP PJI.
Among patients with GN PJI, 17 (89.5%) received intra-
venous antibiotic monotherapy and two (10.5%) received
combined antibiotic therapy (1 with imipenem plus sul-
bactam, and 1 with ciprofloxacin plus amikacin). All but one
patient with GN PJI received at least 4 weeks of intravenous
antibiotic therapy. The antibiotic monotherapy regimen
included treatment with fluoroquinolones in seven cases
(36.8%), carbapenem in three cases (15.8%), extended-
spectrum cephalosporins in six cases (31.6%), and amikacin
in one case (5.2%). Fluoroquinolones were selected for oral
antibiotic switch in patients with GN PJI.
Fig. 1 summarizes the management of PJI in the follow-
up period. The treatment outcomes of GP PJIs and GN PJIs
are listed in Table 3.
In comparison with the GP PJI patients whose pros-
theses could not be preserved, GP PJI patients whose
prostheses could be preserved during the follow-up period
had a shorter interval between onset of infection symp-
toms and surgical intervention (median: 6 days vs. 90 days;
pZ 0.004), shorter total treatment duration, including the
duration of surgical and antibiotic treatment (median: 120
days vs. 303 days; p Z 0.068), and required less debride-
ment (median: 0 vs. 2, p Z 0.013). Among 28 cases of S.
aureus infection, 12 (42.9%) showed preserved prosthesis
after debridement and antibiotic treatment.
Similarly, we also observed that GN PJI patients whose
prostheses could be preserved during the follow-up period
had a shorter interval between onset of infection symptoms
and surgical intervention (median: 6 days vs. 44 days;pZ 0.04), shorter treatment period, including surgical and
antibiotic treatment (median: 247 days vs. 383 days;
pZ 0.48), and required less debridement (median: 0 vs. 2,
p < 0.001) than GN PJI patients whose prostheses could not
be preserved. In 16 cases (40%) of GP PJI and 10 cases
(52.6%) of GN PJI, the prostheses could be preserved during
the follow-up period, despite two GP PJI patients having
a relapse of infection.
Two patients with GP PJI died during PJI treatment: one
patient died from hospital-acquired pneumonia and one
died from PJI. Furthermore, two patients with GN PJI died
during treatment, including one who died because of the
PJI.Discussion
With the increasing number of joint replacements in
Taiwan, over 40,000 patients are expected to receive
a replacement joint in 2011.3e5 On the basis of the reported
occurrence rates of PJIs (0.98%), at least 400 cases of PJI
are estimated to occur annually.23 PJI can increase the cost
of medical treatment12 and may necessitate complicated
and long-term treatment.
In our present study, advanced age was noted more
often in GN PJI cases than in GP PJI cases; a finding similar
to a previous study (median age: 68 years in GN PJI patients
vs. 59 years in GP PJI patients).14 Men accounted for the
majority of the cases (35 cases; 59.3%) in our study; this
finding was similar to the study by Willis-Owen et al.23
Similar to the findings in previous studies,22,24 Gram-
positive bacteria (67.8%) were the dominant microorgan-
isms causing PJIs in our study. S. aureus was the most
common pathogen, consistent with the findings of previous
studies11,25 although other studies have reported Staphy-
lococcus epidermidis as the most common pathogen
causing PJI.22
The rate of GN PJIs in our study (32.2%) was higher than
that reported previously (4e11%).11,24 Polymicrobial infec-
tion accounted for 19% of PJIs in one study, and more cases
of PJIs were due to Gram-positive bacteria.26 However, we
included only monomicrobial PJIs, which might explain the
higher incidence of GN PJIs in our study.
In our study, the infections were classified as early (<3
months), delayed (3e24 months), and late (>24 months),
according to the interval between prosthesis implantation
and onset of infection symptoms.27 The timing of infection
[26 early (44.1%), 20 delayed (33.9%), and 13 late (22.0%)]
in our study showed a trend similar to that observed in
previous studies, which have reported that the infection
incidence declined with time after joint replacement.11,28
However, other studies have reported a higher incidence
of late infections (32%) than delayed infections (23%), and
10% of the cases included in the study were cases of
reinfection.25
In our study, cases of hematogenous infection were more
common in GN PJIs than GP PJIs (36.8% vs. 20%, p < 0.001).
Gram-negative bacterial infections were more common
in the early stage (47.4%) and late stage (36.8%) after
prosthesis implantation. Although previous articles have
mentioned that hematogenous infection and Gram-
negative bacteria infection tended to occur in the early
Figure 1. Clinical management in 59 patients with prosthetic joint infection.
Prosthetic joint infection 367and late stages,13,27 a reasonable explanation for this
phenomenon has not yet been obtained.
Management of Gram-negative bacteria-related bone
and joint infection is complicated29 because biofilms may
form under the antibiotic-loaded bone cement30 and drug-
resistant microorganisms may cause infections, thereby
restricting the available choices for oral antibiotics.31
Furthermore, only a few studies have investigated Gram-
negative bacteria-related bone and joint infection, espe-
cially PJIs.14,32 Our study showed that patients with GN PJIs
required longer treatment, including surgical and antibiotictreatment (median: 259 days vs. 161 days; p Z 0.04), and
longer hospital stay (median: 31 days vs. 22 days; pZ 0.07)
than those with GP PJIs. Legout et al have reported
a similar trend, in which longer antibiotic therapy (6e9
months) was necessary to treat Gram-negative bacteria-
related bone and joint infections.32
We found that a shorter interval (range: 1e10 days)
between the onset of infection symptoms and surgical
treatment was related to successful prosthesis retention in
GN PJI and GP PJI patients. This was similar to two reports
stating that prostheses were preserved when the cases
Table 3 22 GP PJI and 17 GN PJI patients treated with debridement and prosthesis retention
Characteristics GP PJI (n Z 22) GN PJI (n Z 17)
Prosthesis
retentiona
(n Z 16)
Prosthesis
removalb
(n Z 6)
p
value
Prosthesis
retention
(n Z 10)
Prosthesis
removal
(n Z 7)
p
value
Age (yr), median age (range) 63 (34e85) 62 (46e73) 0.93 56 (27e73) 63 (33e79) 0.38
Male sex 10 (62.5) 2 (33.3) 0.4 7 (70) 5 (71.4) 0.37
Clinical symptoms
pain 13 (81.2) 5 (83.3) 0.66 7 (70) 6 (85.7) 0.25
swelling 12 (75) 5 (83.3) 0.61 6 (60) 5 (71.4) 0.10
limited range of motion 8 (50) 2 (33.3) 0.2 1 (10) 2 (28.5) 0.25
local heat 7 (43.7) 2 (33.3) 0.8 1 (10) 1 (14.2) 0.12
Fever (38.3C) 0 (0) 4 (66.6) NA 1 (10) 0 (0) NA
discharge sinus 7 (43.7) 3 (50) 0.5 3 (30) 3 (42.8) 0.71
Symptom durationc median
days (range)
6 (1e10) 90 (30e120) 0.004 6 (2e8) 44 (31e155) 0.04
Laboratory finding median (range)
ESR (mm/hr) 62 (25e140) 70 (18e108) 0.24 29 (7e140) 74 (22e140) 0.9
WBC (103 cells/mL) 9.94 (4.3e18.2) 9.39 (4.2e38.6) 0.81 7.44 (4.1e19.1) 9.62 (4.5e10.7) 0.9
Comorbidity
DM 2 (12.5) 2 (33.3) 0.66 1 (10) 2 (28.5) 0.75
ESRD 0 (0) 1 (16.6) NA 0 (0) 1 (14.2) NA
gouty arthritis 1 (6.2) 0 (0) NA 0 (0) 0 (0) NA
liver cirrhosis 0 (0) 1 (16.6) NA 0 (0) 0 (0) NA
Treatment
total treatment daysd median
days (range)
120 (60e290) 303 (119e877) 0.068 247 (109e1100) 383 (120e1979) 0.48
debridement median times (range) 0 (0e1) 2 (1e5) 0.013 0 (0e1) 2 (1e4) <0.001
Number (%) of patients, unless indicated. Data with p < 0.05 were considered to be statistically significant.
DM Z diabetes mellitus; ESR Z erythrocyte sedimentation rate; ESRD Z end-stage renal disease; GN PJI Z Gram-negative prosthetic
joint infection; GP PJI Z Gram-positive prosthetic joint infection; NA Z not applicable; WBC Z white blood cells.
a Successful debridement and prosthesis retention during the follow-up period.
b Failure of prosthesis retention due to relapse of infection during the follow-up period.
c Duration of infectious symptoms prior to surgical intervention.
d Duration included medical and surgical treatment.
368 S.-W. Tseng et al.showed a shorter interval between onset of infection
symptoms and surgical intervention (4.85 days and 8 days,
respectively).17,33
In this context, a few studies have discussed GN PJIs. In
GN PJI patients with a median of 6 days (range: 2e8 days)
between onset of infection symptoms and surgical inter-
vention, the prostheses were preserved successfully, and
these patients required shorter antibiotic treatment and
less surgical debridement than patients with an extended
period of infection symptoms. Hsieh et al also have
observed that GN PJI patients who had a shorter interval
between onset of infection symptoms and surgical inter-
vention showed better outcomes.14 However, long-term
antibiotic treatment was needed in our GN PJI group
(median: 247 days; range: 109e1100 days) for eradication
of infection, compared to the 91 days of antibiotic treat-
ment required in the study by Hsieh et al.14 This difference
in treatment time might have been due to different patient
populations and treatment strategies. However, treatment
success and failure in PJI might be related not only to early
surgical intervention, but also to disease severity andunderlying comorbid conditions; all these factors influence
the surgical management and clinical outcome.
The limitation of the current study was that it was
difficult to discern whether the effect of early or late
surgical intervention was confounded by the disease
severity per se. For patients who underwent early surgical
intervention, the low disease severity might have helped
the surgeons perform operations with less debridement,
thereby ensuring shorter treatment duration. In contrast,
patients whose prostheses were eventually removed might
have experienced more comorbidity, requiring the surgeons
to delay the surgery and perform it with more debridement.
Thus, successful prosthesis retention might not be truly
related to early surgical intervention; rather it may be
related to disease severity and underlying condition. There
was no standard treatment for PJI, therefore, differences
between the findings of our study and other studies might
have been due to different treatment regimens or patient
populations. An ideal therapeutic strategy to achieve
favorable outcomes could be identified from the results of
further prospective multicenter studies.
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